Displaying 34 (all) recruiting clinical trials.
-
A PHASE Ib/II OPEN-LABEL MULTICENTER STUDY EVALUATING THE SAFETY ACTIVITY AND PHARMACOKINETICS OF GDC-6036 IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC NON?SMALL CELL LUNG CANCER WITH A K
This study is for people with advanced or metastatic non-small cell lung cancer (NSCLC) containing a specific KRAS G12C mutation. The study is testing a ...
-
Phase 1 First-in-Human Dose Escalation and Expansion Study to Assess Safety and Tolerability of Intravenous Administration of ICVB-1042 in Patients with Advanced Solid Tumors
This study is about a new medicine called ICVB-1042 (kills tumor cells) for people with advanced solid tumors. It has two parts: one where we ...
-
A phase I open-label multi-center study of KFA115 as a single agent and in combination with tislelizumab in patients with select advanced cancers
This study is testing a new medicine called KFA115 (FDA approved) for patients with advanced or widespread cancers. It has two main parts: one where ...
-
The HistoSonics Edison System for treatment of primary solid renal tumors using histotripsy (#HOPE4KIDNEY US)
This study is testing the HistoSonics Edison System for treating kidney tumors using histotripsy (involves using focused ultrasound beams from outside the body to create ...
-
RevMed RMC-6236-001: A Phase 1/1b Multicenter Open-Label Study of RMC-6236 in Subjects with Advanced Solid Tumors Harboring Mutations in KRAS at Position G12.
This study is testing a new medicine, RMC-6236, for patients with certain advanced cancers that have specific changes in a gene called RAS. RMC-6236 aims ...
-
A Phase 1b Study to Evaluate the Safety Tolerability and Preliminary Efficacy of ATP150/ATP152 VSV-GP154 and Ezabenlimab (BI 754091) in Patients with KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma
This study is designed for patients with resected KRAS G12D/G12V mutated pancreatic cancer.This is an open-label, phase 1b study comprising of two parts ...
-
A Phase I Multicenter Open-label First-in Human Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors
This study is designed for patients diagnosed with advanced solid tumors. This is a study for the first time testing of a new medicine called ...
-
A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 AN ANTI-CD22 X ANTI-CD28 COSTIMULATORY BISPECIFIC MONOCLONAL ANTIBODY IN COMBINATION WITH ODRONEXTAMAB AN ANTI-CD20 X ANTI-CD3 BISPECIFIC MONOCLONAL ANTIBODY IN PATIENTS WITH AGGRESSIVE
The goal of this study is to investigate how safe and effective the combining of two different antibodies, REGN5837 and odronextamab (REGN1979), is in patients ...
-
Phase 1 First-In-Human Study to Explore the Safety Tolerability and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
This study is investigating a drug called AMG 305, which is designed to target specific cancer cells that have CDH3 and MSLN. This is a ...
-
A Master Protocol for the Multi-Cohort Phase 1/2 Study of DCC-3116 in Combination with Anticancer Therapies in Participants with Advanced Malignancies
This study is testing a medicine called DCC-3116 along with other cancer treatments for patients with advanced malignancies. The study team split the study into ...